Pfizer’s Phase 3 Study of Gene Therapy for DMD
In this webinar, Beth Belluscio, MD, PhD, Pfizer Global Clinical Lead for Rare Neurological Disorders, discusses the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Dr. Belluscio answers questions from the Duchenne community about the study including aspects of the design and the criteria for enrollment, followed by a Q&A session about the study facilitated by CureDuchenne. Pfizer answers as many questions as possible to ensure that the Duchenne community is well-informed. Please know that, in this forum, Pfizer is not able to answer questions about the ongoing Phase 1b study.
Beth Belluscio MD, PhD | Pfizer Global Clinical Lead for Rare Neurological Disorders
You’ll be prompted to enter your name and email address to view the recording.
Clinical Trial Information
For more information regarding the Pfizer Phase III clinical trial “A Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy”, click here »
Note: Pfizer’s information will only be available after it is posted on www.clinicaltrials.gov.